Embold Therapeutics
Redwood City, US · Founded 2023 · Delaware corporation
Biotech
Founders & leadership
GW
Gjalt W. HuismanNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$3M disclosed across 2 rounds · 2026
▶$2.5MraisedJul 2026 · 7 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJul 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gjalt W. HuismanExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2.5M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$500KraisedFeb 2026 · 1 investors · Biotechnology
▶$500KraisedFeb 2026 · 1 investors · Biotechnology
Officers, directors & promoters on the filing
- Gjalt W. HuismanExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 04
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Embold Therapeutics raised?
- Embold Therapeutics has disclosed $3M raised across 2 rounds.
- Where is Embold Therapeutics headquartered?
- Embold Therapeutics is headquartered in Redwood City, US.